Status:
COMPLETED
A Study Using Surveys to Learn More About Treatment With Steroidal Mineralocorticoid Receptor Antagonists, How They Are Used, What Side Effects They Have, and How Satisfied People Who Receive Them Are in the US
Lead Sponsor:
Bayer
Conditions:
Chronic Kidney Disease
Type 2 Diabetes Mellitus
Eligibility:
All Genders
18+ years
Brief Summary
This is an observational study in which patients with chronic kidney diseases (CKD), type 2 diabetes (T2D) or heart failure (HF) who are current or past users of sMRA therapies are studied. sMRA stand...
Eligibility Criteria
Inclusion
- Currently active with commercial or Medicare Advantage health insurance (both medical and pharmacy benefits) at the time the patient sample is identified
- ≥1 pharmacy claim for a sMRA therapy (spironolactone or eplerenone) in the most recent 12-months of claims data
- ≥1 inpatient or ≥2 outpatient medical claims with an International Classification of Diseases, Ninth/Tenth Revision, Clinical Modification (ICD-9/10-CM) diagnosis code for CKD, T2D or HF going back to 1 Jan 2006
- Age ≥18 years at the end of the patient identification period
- Has email and/or mailing address
- Consent to participate in the survey
Exclusion
- \- None
Key Trial Info
Start Date :
November 2 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 13 2023
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT05407662
Start Date
November 2 2022
End Date
June 13 2023
Last Update
September 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations
Whippany, New Jersey, United States, 07981